BioSyent (TSX-V: RX) (OTC: BIOYF) is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada. SNNLive spoke with Rene Goehrum, President and CEO of BioSyent Inc. at the 3rd Annual Marcum MicroCap Conference 2014 in New York City, NY.
“What we do is we look for unique innovative medications that are not available in Canada, we source them primarily from the United States and Europe, and then we license them for commercialization in Canada” begins Mr. Geohrum. He continues, “So we take it right through the approval process with Health Canada, we’ve got a full sales team and a marketing team and then we commercialize in the Canadian market.”
Mr. Goehrum explains, “We’ve been able to penetrate the market more with our sales and marketing approach than others have done with the same compound or the same molecule.” He adds, “We look for opportunities where we can work with the reimbursement system and also work around it.” For more information, check out their website at www.biosyent.com.
© 2017 Stock News Now
Supported by Superior Web Solutions